Evidence Level
Sea moss research is largely preclinical and compositional, with very few human clinical trials directly studying Chondrus crispus or Gracilaria supplementation. The strongest evidence relates to its iodine content — seaweed is a well-established natural iodine source, and iodine's role in thyroid health is thoroughly documented (Teas et al., 2004; Zava & Zava, 2011). Pereira (2011) published comprehensive mineral analyses confirming that red seaweeds contain significant concentrations of essential macro- and trace minerals. The bioactive polysaccharides (carrageenans) have been studied extensively in vitro: Liu et al. (2015) demonstrated prebiotic effects on beneficial gut bacteria, while Leibbrandt et al. (2010) showed carrageenan-derived compounds inhibited influenza virus entry into cells. However, the '92 minerals' marketing claim lacks peer-reviewed verification, and carrageenan itself has generated controversy — degraded carrageenan (poligeenan) causes inflammation in animal models, though food-grade carrageenan appears safe at typical intakes (McKim, 2014). The primary research gap is the near-total absence of randomized controlled trials in humans studying sea moss supplementation for any specific health outcome.